Merck & Co. Inc. (MRK) Q1 2026 (USD): Adj. EPS -1.28 (exp. -1.47), Revenue 16.29bln (exp. 15.85bln), Keytruda sales 8bln (exp. 7.62bln)
Importance
Level 1
- Q1 GAAP and non-GAAP loss per share include USD 3.62/shr charge for acquisition of Cidara.
Guidance:
- FY adj. EPS 5.04-5.16 (exp. 5.10).
- FY sales 65.8-67bln (exp. 66.6bln).